Date: 2011-11-02
Type of information: R&D agreement
Compound: HuCAL antibody technology and additional proprietary technology modules for research in drug discovery
Company: MorphoSys (Germany) Shionogi (Japan)
Therapeutic area:
Type agreement: R&D licensing
Action mechanism:
Disease:
Details: MorphoSys and Shionogi have agreed a three-year extension of their research partnership. The german biotech company has expanded its current licence agreement with the japanese pharmaceutical groupe. The expanded agreement covers the use of MorphoSys's HuCAL antibody technology and additional proprietary technology modules for research in drug discovery for three additional years and will be run by the company's AbD Serotec unit. Under the terms of the agreement, Shionogi will continue to have the right to use MorphoSys's patented antibody library HuCAL PLATINUM for research purposes at one of its research sites. MorphoSys and Shionogi signed a first license agreement on the use of MorphoSys\'s HuCAL technology in September 2005.
Financial terms: MorphoSys will receive annual user fees from Shionogi for access to the technologies. Further financial details were not disclosed.
Latest news:
